<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schmiege P</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of General Medical Sciences</funding><funding>U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS)</funding><funding>NHLBI NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Heart, Lung, and Blood Institute</funding><funding>G. Harold and Leila Y. Mathers Foundation</funding><funding>Welch Foundation</funding><funding>G. Harold and Leila Y. Mathers Foundation (G. Harold &amp; Leila Y. Mathers Foundation)</funding><funding>U.S. Department of Health &amp; Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)</funding><funding>NIGMS NIH HHS</funding><pagination>5325</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12174366</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>TRPML2 activity is critical for endolysosomal integrity and chemokine secretion, and can be modulated by various ligands. Interestingly, two ML-SI3 isomers regulate TRPML2 oppositely. The molecular mechanism underlying this unique isomeric preference as well as the TRPML2 agonistic mechanism remains unknown. Here, we present six cryo-EM structures of human TRPML2 in distinct states revealing that the π-bulge of the S6 undergoes a π-α transition upon agonist binding, highlighting the remarkable role of the π-bulge in ion channel regulation. Moreover, we identify that PI(3,5)P&lt;sub>2&lt;/sub> allosterically affects the pose of ML2-SA1, a TRPML2 specific activator, resulting in an open channel without the π-α transition. Functional and structural studies show that mutating the S5 of TRPML1 to that of TRPML2 enables the mutated TRPML1 to be activated by (+)ML-SI3 and ML2-SA1. Thus, our work elucidates the activation mechanism of TRPML channels and paves the way for the development of selective TRPML modulators.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>TRPML2 in distinct states reveals the activation and modulation principles of the TRPML family.</pubmed_title><pmcid>PMC12174366</pmcid><funding_grant_id>R35 GM149533</funding_grant_id><funding_grant_id>MF-2302-03702</funding_grant_id><funding_grant_id>P01HL160487</funding_grant_id><funding_grant_id>R35GM149533</funding_grant_id><funding_grant_id>I-1957</funding_grant_id><funding_grant_id>P01 HL020948</funding_grant_id><pubmed_authors>Hatton A</pubmed_authors><pubmed_authors>Jaslan D</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Sadanandan NP</pubmed_authors><pubmed_authors>Fine M</pubmed_authors><pubmed_authors>Elghobashi-Meinhardt N</pubmed_authors><pubmed_authors>Schmiege P</pubmed_authors><pubmed_authors>Grimm C</pubmed_authors></additional><is_claimable>false</is_claimable><name>TRPML2 in distinct states reveals the activation and modulation principles of the TRPML family.</name><description>TRPML2 activity is critical for endolysosomal integrity and chemokine secretion, and can be modulated by various ligands. Interestingly, two ML-SI3 isomers regulate TRPML2 oppositely. The molecular mechanism underlying this unique isomeric preference as well as the TRPML2 agonistic mechanism remains unknown. Here, we present six cryo-EM structures of human TRPML2 in distinct states revealing that the π-bulge of the S6 undergoes a π-α transition upon agonist binding, highlighting the remarkable role of the π-bulge in ion channel regulation. Moreover, we identify that PI(3,5)P&lt;sub>2&lt;/sub> allosterically affects the pose of ML2-SA1, a TRPML2 specific activator, resulting in an open channel without the π-α transition. Functional and structural studies show that mutating the S5 of TRPML1 to that of TRPML2 enables the mutated TRPML1 to be activated by (+)ML-SI3 and ML2-SA1. Thus, our work elucidates the activation mechanism of TRPML channels and paves the way for the development of selective TRPML modulators.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2026-06-03T07:55:22.556Z</modification><creation>2026-04-26T03:10:41.392Z</creation></dates><accession>S-EPMC12174366</accession><cross_references><pubmed>40527873</pubmed><doi>10.1038/s41467-025-60710-8</doi></cross_references></HashMap>